Fusions of the lac operon to genes induced by treatment with sublethal levels of alkylating agents have been selected from random insertions of the Mu-dl(ApRlac) phage by screening for induction of f3-galactosidase activity in the presence of methyl methanesulfonate. Genetic analysis reveals that these fusions resulted from insertion of Mu-dl(ApRlac) into two regions of the chromosome. One region (aidA) is near his and, based on phenotypic effects, appears to represent insertion into the alkA gene. The other region (aidB) is in the 92.3-to 98-min region, which harbors no previously identified genes involved in repair of alkylation damage. The aidB fusions caused increased resistance to alkylating agents and caused little or no change in the biological effects of adaptation to alkylating agents. Unlike the aidA fusions, aidB fusions showed increased f8-galactosidase activity in untreated cells in a growth phase-dependent fashion. The ada-5 mutation, which blocks expression of the adaptive response, decreased induction of i-galactosidase activity in both aidA and aidB fusions after alkylation treatments. Thus, both aidA and aidB share with adaptive response a common regulatory mechanism involving the ada gene. The growth phase-dependent control of the aidB fusions, however, is unaffected by ada, suggesting that a second regulatory mechanism exists that controls only aidB.
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When cells of Escherichia coli are treated with sublethal levels of alkylating agents for several generations, the mutagenic and lethal effects of subsequent high-level treatments are decreased (1, 2) . This induced resistance to the deleterious effects of alkylating agents is termed the adaptive response. Based on genetic and physiological studies, the adaptive response is thought to be due to the induction of specific gene products that act to repair alkylation-induced lesions in DNA (1) .
Subsequent biochemical studies have confirmed that at least two gene products are induced by such adaptive treatments (3) (4) (5) (6) . Both of these products act to repair specific lesions produced in DNA by alkylating agents. One of the induced enzymes is a glycosylase, the product of the alkA gene, which removes N3-methyladenine, N3-methylguanine, and N7-methylguanine (5, 6) . The second induced gene is a methyltransferase that removes the methyl group from o6_ methylguanine (3, 4) .
The adaptive response is controlled by the ada gene (7, 8) . The molecular mechanism(s) by which ada functions is not known, although recent evidence suggests it may be a positive regulator (ref. 9 ; P. LeMotte and G. Walker, personal communication). Different isolates of ada mutants show different effects on the protection against lethality and mutagenesis resulting from adaptation. Some ada mutants block one induced repair response more than the other, and no correlation exists between protection against killing and mutagenesis (7) . This is consistent with the hypothesis that at least two different products are induced by adaptive treatments-one that repairs lesions that are primarily lethal, and one that repairs lesions that are primarily mutagenic.
To expand our understanding of the adaptive response and to identify genes induced specifically by alkylation treatments, we have begun to search for mutants in this process by using the phage Mu-dl(ApRlac) as a mutagen (10) . This phage inserts into the E. coli chromosome in an apparently random fashion (10) . The lac gene carried by this phage lacks a promoter and is, therefore, not expressed. When insertion of this phage occurs next to a promoter and in the proper orientation, p-galactosidase transcription can occur (10) . In addition, since p-galactosidase is synthesized only from the external promoter, it is subject to the regulatory mechanisms that control this promoter. Moreover, because the largest target for insertion is generally the protein-coding sequence of the gene, mutant phenotypes frequently result from insertion. Thus, mutant phenotypes can provide insights into the functions of the afflicted genes.
In this study, we selected insertions of Mu-dl(ApRlac) that place p-galactosidase synthesis under the regulation of promoters of genes induced by treatments with methyl methanesulfonate (MeSO). We describe the isolation of such mutants, the genetic loci, their response to MeSO and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) in crude extracts at various times after treatment. P-Galactosidase activities were assayed essentially as described by Miller (15) , using the chloroform lysis method. In addition, an A6w measurement always accompanied the production of each crude extract in order to normalize to cell density.
Genetic Methods. P1-transductions were carried out by the method of Willets et al. (14) . Matings were done by mixing donors and recipients (5:1) in wells of a microtiter plate and incubating for 2 hr at 30TC. After incubation, the microtiter plates were placed on ice. The cultures were then diluted, mixed in a Vortex to break up mating pairs, and plated on selective media. Either Arg' SmR or Thr' Leu+ SmR recombinants were selected and tested for recombination between the aid' and aid::Mu-dl(ApRlac) by screening for loss of the ApR phenotype. In each cross, at least 100 recombinants of each type were selected and tested for loss of the ApR marker.
Adaptation. Cells were grown overnight in minimal medium (E salts; glucose, 0.4%; Bacto Casamino acids, 0.2%; thiamine, 0.2,ug/ml), diluted 1:25, and regrown to =108 cells per ml. MNNG was added at the inducing concentration, and the cells were grown for another 2 hr to elicit the adaptive response. Cell concentrations were then readjusted to =108 cells per ml, and the cultures were treated with several challenge doses of MNNG for 30 min at 30°C. The inducing doses were the highest that showed no effect on growth or mutagenesis. For strains MV1161, MV1561, MV1563, and MV1564, the inducing dose of MNNG was 1,ug/ml and the challenge doses of MNNG routinely used were 5, 10, 20, 40, 60, 90, and 120 ,ug/ml. For strains MV1565 and MV1571, the inducing dose was 0.1 ,ug/ml and the challenge doses of MNNG usually used were 1, 2.5, 5, 10, 20, and 40 ug/ml. To determine survival after challenge, cells were immediately diluted 1:100 and chilled, then diluted further and plated on DSEM plates (16) RESULTS Isolation of Mu-dl(ApRlac) Insertion Mutants. Our screening procedure yielded 10 mutants (from ==120,000 ApR colonies screened) that exhibited increased levels of f3-galactosidase activity after treatment with MeSO. Since MeSO induces both the adaptive response and the SOS response (17, 18) , all Mu-dl(ApRlac) insertion mutants were first tested for ,f3galactosidase induction by UV. Of the 10 mutants, 5 were UV-inducible and were assumed to be insertions in genes of the SOS system similar to those isolated by Kenyon and Walker (19) . The other 5 were inducible by alkylating agents but not by UV. These were termed alkylating-agent inducible (aid) mutants.
Genetic Mapping of the aid::Mu-dl(ApRlac) Insertions. The aid::Mu-dl(ApRlac) insertions were assigned to approximate genetic loci either by P1-transduction or by mating with several Hfr strains. In both cases, recombinants were selected that had lost specific auxotrophic markers and were then tested for concomitant loss of the ApR marker. The approximate map positions of all aid::Mu-dl(ApRlac) mutations are shown in Fig. 1 , together with the origins of transfer of the relevant Hfr strains.
To test for possible insertion into alkA, all strains were tested for linkage of aid: :Mu-dl(ApRlac) insertions to the his operon by P1-mediated transduction using P1lKL14(his' aid+). The aid::Mu-dl(ApRlac) mutations in strains MV1565 and MV1571 were found to be linked to the his operon with cotransduction frequencies of 20% and 18%, respectively.
The insertions in strains MV1561, MV1563, and MV1564 were assigned to the 91-to 98-min region on the basis of the following results. Ampicillin-sensitive recombinants were recovered at a frequency of 31%-50% among Thr+ Leu+ SmR recombinants from crosses of each of these strains with Hfr donor strains KL14 and Ra2, and at a frequency of 31%-62% among Arg+ SmR recombinants from crosses of each of these strains with Hfr strains P801, BW113, and KL226. In contrast, no ampicillin-sensitive recombinants were recovered among 100 Arg+ SmR recombinants from each cross of MV1561, MV1563, and MV1564 with Hfr KL209, or among 100 Thr+ Leu+ SmR recombinants from each cross of these three recipients with HfrH. Thus, the Mu-dl(ApRlac) insertions in these three strains lie in the region transferred by Hfr strains KL14, Ra2, P801, BW113, and KL226, and must lie between the origins of transfer of Hfr strains KL209 and HfrH. Genetics: Volkert and Nguyen (20) to convert cotransduction frequency to map distance and taking into account the 9.3-kilobase inclusion of TnWO in the P1 donor, each of the aid::Mu-dl(ApRlac) insertions lies more than 1.3 min from malE. Thus, the aidB gene(s) resides in the 92.3-to 98-min region of the E. coli chromosome.
Induction of P-Galactosidase Activity by DNA Damaging Agents. ,B-Galactosidase induction kinetics of representative aid::Mu-dl(ApRlac) mutations are shown in Fig. 2 . Based on the phenotypic and genetic characteristics, there appear to be two aid mutations: aidA, which is present in strains MV-1565 and MV1571 and aidB, which is present in strains MV1561, MV1563, and MV1564. Minor phenotypic variations are seen when individuals of either the aidA or aidB groups are compared with one another; it is not clear whether these variations are due to insertion into different genes or allelic variation resulting from insertion into different sites within a single gene. Further study of the individuals within a group will be required to answer this question.
All strains were compared for induction of l3-galactosidase activity by MeSO and MNNG at two doses-the optimal dose for expression of the adaptive response, and the dose that yields maximal expression of,-galactosidase activity, which is a reflection of the optimal expression of the aid genes (aid response). In wild-type AB1157 derivatives, the optimal dose for expression of the adaptive response by MeSO is 0.01% (18) . sponse and the dose for maximal induction of 3galacto-sidase activity are 10-fold greater in aidB than in aidA. For wild type and aidB, the optimal dose for expression of the adaptive response by MNNG was determined to be 1 pig/ml; for aidA, it was 0.1 pug/ml (see section on effects of aid::Mudl(ApRlac) insertions on the adaptive response). When MNNG is used as the inducing agent at the optimal dose for expression of the adaptive response, only aidA shows induction of /3-galactosidase activity (Fig. 2B) . Only when higher doses of MNNG (10 pug/ml) are used is /3-galactosidase induction seen in aidB (Fig. 2B) . Thus, MNNG induces aidB strains but not when used at levels that induce the adaptive response in these strains (see below).
Maximal induction of /-galactosidase activity by MNNG is attained in aidB at 10 pzg/ml and in aidA at 1 ug/ml (Fig.  2B) . When induction of f3-galactosidase activity by the two agents, MeSO and MNNG, is compared, MNNG is a better inducing agent than MeSO in aidA. In aidB, the opposite is true and MeSO is a better inducing agent.
Effect of ada-5 on Induction of (-Galactosidase Activity. The ada-S mutation was introduced into each of the aid mutants. The optimal dose for induction of /3-galactosidase activity was decreased by ada-S in the aidB mutants, but not in the aidA mutants. When /3-galactosidase activity was compared under optimal /3-galactosidase-inducing conditions for each strain, both aidA and aidB showed decreased 3-galactosidase induction when the ada-S mutation was present (Table 1). Thus, both aidA and aidB are influenced by ada and appear to be under its regulatory control.
Constitutive Expression of .8-Galactosidase Activity. The aidB strains showed a small increase in ,-galactosidase activity even in untreated cells (Fig. 2A) . To further examine this effect, the assay was extended. The results are shown in Fig. 3 , together with growth curves monitored by absorbance at 600 nm. The aidB strains showed increasing 3-galactosidase activities in untreated cells. This increase began during the late logarithmic phase of the growth cycle. When the cells reached stationary phase, the f3-galactosidase activity stabilized at a level 5-10 times higher than that seen in logarithmically growing cells. This is not a general feature of aid insertions, because aidA strains did not show this derepression (Fig. 3) . Thus, the increase in 3-galactosidase activity in these strains is indicative of specific derepression of aidB fusions. Unlike the induction seen in response to alkylation treatment, the induction in undamaged cells is unaffected when ada-S is introduced into aidB strains (Fig. 3) . Therefore, this type of regulation appears not to be controlled by the ada gene. (19) .
In this study, we use the term adaptive response to refer to the biological effects of sublethal treatments with alkylating agents (i.e., decreased lethality and mutagenesis after subsequent challenge treatments). The term aid response refers to the induction of genes by alkylation treatments. We make this distinction because the involvement of aid genes in the adaptive response is not clear, nor will all aid mutations necessarily share the same regulatory elements with the genes of the adaptive response.
The aidA insertion mutants contained Mu-dl(ApRlac) insertions that mapped near the his operon, increased sensitivity to alkylating agents, and blocked adaptation to the lethal effects but not the mutagenic effects of alkylation damage.
The similarity of the phenotype of aidA to that of an alkA mutant and their similar linkage to the his operon (6, 21) The link between the adaptive response and the induction of aid mutations is indicated by their common regulation by the ada gene. The ada-S mutation decreases expression of both the adaptive response (7) and the induction of P-galactosidase activity in all aid: :Mu-dl(Ap'lac) fusion strains.
Thus, both the aid response and the adaptive response are controlled by the ada gene.
Although all of the aid genes require ada' for induction by alkylation treatment, an additional regulatory mechanism must also control aidB, based on the lack of effect of ada-S on the induction of /3-galactosidase in undamaged cells. 
